NAGEConsumer Defensive · Packaged FoodsThe 6 Wall Street analysts covering Niagen Bioscience, Inc. hold a median 12-month price target of $11 — +315.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 14 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Niagen Bioscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (98): The business earns solid, repeatable profits on what it owns.
Momentum (7): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NAGE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +315.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | $12 → $11 |
| 5 May 2026 | Canaccord Genuity | Maintains | Buy | $13 → $10 |
| 31 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 5 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 5 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 11 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 June 2025 | Canaccord Genuity | Maintains | Buy | — |
| 6 June 2025 | Roth Capital | Maintains | Buy | — |
| 27 May 2025 | Canaccord Genuity | Initiates | Buy | — |
| 8 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Mar 2025 | Ladenburg Thalmann | Maintains | Buy | — |
| 6 Nov 2024 | Roth MKM | Maintains | Buy | — |
| 4 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NAGE appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Niagen Bioscience, Inc. returned −66.1% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 49% of US stocks
Cheaper than 57% of US stocks
Cheaper than 36% of US stocks
Cheaper than 22% of US stocks
Higher than 21% of US stocks
Higher than 6% of US stocks
Higher than 78% of US stocks
Higher than 49% of US stocks
Higher than 74% of US stocks
Higher than 83% of US stocks
Higher than 79% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Niagen Bioscience, Inc. has a market value of $204.1M and an enterprise value of $144.3M.
Revenue in the twelve months to 30 June 2026: $129.1M. The latest quarter shrank 4.3% year on year.
Net income over the same four quarters: $16.0M, a 12.4% net margin.
Diluted earnings per share, trailing twelve months: $0.18.
Free cash flow in the twelve months to 30 June 2026: $5.7M.
Trailing P/E: 13.6×; forward P/E: −43.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Niagen Bioscience, Inc. employs 117 people — $1.1M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Niagen Bioscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Niagen Bioscience announced it will report its third-quarter 2026 financial results after market close on November 4, 2026, and hold a conference call at 4:30 p.m. ET that day. The quarter ended September 30, 2026.
Why it matters — NAGE watchers can note when the company plans to release its quarterly results and discuss them on a conference call.
Niagen Bioscience announced that Radicle Science and the Council for Responsible Nutrition honored Andrew Shao, Ph.D., the company’s Senior Vice President of Global Regulatory and Scientific Affairs, with the 2026 Annette Dickinson Trailblazer Award.
Why it matters — The recognition highlights an award received by a senior Niagen Bioscience executive in regulatory and scientific affairs.
Niagen Bioscience said senior management will participate in the 20th Annual LD Micro Main Event in Los Angeles, October 19–21, 2026. CEO Robert Fried is scheduled to present on October 21 at 1:30 p.m. PT.
Why it matters — The event provides NAGE watchers with a scheduled opportunity to hear from the company’s CEO.
Niagen Bioscience announced the launch of "Don't Get Old. Age Better.®," a new brand campaign for its Niagen®, Tru Niagen®, and Niagen Plus™ products, featuring 11-time world champion surfer Kelly Slater and more than 20 partners across sports, entertainment, and medicine. The campaign draws on 25 years of NAD+ science.
Why it matters — NAGE watchers would care because this new brand campaign with high-profile partners aims to raise consumer awareness and visibility of the company's NAD+ product lineup.
Niagen Bioscience announced a Start-Up Agreement with Mass General Brigham (MGB) investigators to begin detailed planning for what is envisioned to be the largest and most comprehensive clinical trial of Niagen (patented nicotinamide riboside) to date, focused on healthy aging.
Why it matters — A large, first-of-its-kind healthy aging trial with a prestigious institution like Mass General Brigham could advance the clinical evidence base for Niagen.
The 6 Wall Street analysts covering Niagen Bioscience, Inc. have a median 12-month price target of $11, with estimates ranging from $8.5 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Niagen Bioscience, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Niagen Bioscience, Inc. 52 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Niagen Bioscience, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +315.0% from the last close, and Ticker Nerd's factor model ranks Niagen Bioscience, Inc. 52 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Niagen Bioscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NAGE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8.5 to $22 over the next 12 months.
Niagen Bioscience, Inc. returned -66.1% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Niagen Bioscience Inc. is a bioscience company focused on healthy aging and NAD+ science.
The most recent item we track (Business Wire, 15 Oct 2026): "Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026". Niagen Bioscience announced it will report its third-quarter 2026 financial results after market close on November 4, 2026, and hold a conference call at 4:30 p.m. ET that day. The quarter ended September 30, 2026.
Niagen Bioscience Inc. is a bioscience company focused on healthy aging and NAD+ science. It develops and commercializes proprietary ingredient technologies and finished dietary supplement products centered on nicotinamide riboside and related NAD+ precursors. The company serves consumer, ingredient, analytical reference standards and services, and pharmaceutical markets through products used in dietary supplements, food and beverage formulations, skin care applications, and research settings. Niagen Bioscience also supplies ingredient raw materials to manufacturers and supports scientific and quality-control work through its analytical and reference standards offerings. Its current portfolio is built around the Niagen platform, which anchors the company’s consumer brands and broader ingredient business, making Niagen Bioscience a specialized participant in the health and wellness, nutraceutical, and bioscience sectors.
CEO Mr. Robert N. Fried · 117 employees · United States · https://www.niagenbioscience.com
